Evaxion Q2 FY26 net loss narrows to USD 3.7 million; revenue posts no revenue
EVAX•Q2 loss narrows as expenses shift
Evaxion reported Q2 2026 net loss of USD 3.7 million, improving from a USD 4.8 million loss in Q2 2025.
Operating loss narrowed to USD 3.85 million from USD 4.34 million a year earlier; finance expense fell to USD 0.1 million from USD 0.7 million.
R&D spending rose to USD 2.33 million from USD 2.17 million, while G&A expense dropped to USD 1.51 million from USD 2.21 million.
Cash position and pipeline updates
Cash slid to USD 14 million at June 30 from USD 18.4 million at March 31; runway unchanged into H2 2027.
Pipeline update flagged EVX-01 three-year melanoma data at ESMO 2026; EVX-04 filing expected before year-end; EVX-05 added.
